Sabrina Serani

ChatGPT was able to answer general questions about genetic counseling for gynecologic cancers, but some obstacles still remain.

The biologics license application from the FDA is supported by data from the phase 3 TROPION-Breast01 trial of datopotamab deruxtecan in HR-positive, HER2-negative breast cancer.

A quality initiative study investigated whether offering human papillomavirus vaccines at the time of abortion care could increase vaccination rates.

Betty Hamilton, MD, discussed findings from a quality of life study in patients with FLT3 ITD-positive acute myeloid leukemia who underwent allogeneic stem cell transplant.

Chelsea Peterson, DO, discussed a real-world study investigating ruxolitinib in patients with steroid-refractory graft-vs-host disease.

Michael Scordo, MD, discussed findings from a phase 2 study investigating new antithymocyte globulin dosing models for ex vivo CD34-selected allogeneic stem cell transplants.

The American Society of Clinical Oncology has updated its recommendations for patients with cancer on which vaccines to receive or avoid.

Findings from the phase 3 METIS trial found that tumor-treating fields were able to significantly improve time to intracranial progression in patients with brain metastases from non-small cell lung cancer.

According to a subset analysis of the phase 3 MARIPOSA trial, dose interruptions during the course of amivantamab and lazertinib treatment were still effective in EGFR-mutant non-small cell lung cancer.

A novel CAR T-cell therapy being developed at City of Hope offers a potential new treatment avenue for patients with recurrent glioblastoma and high-grade glioma. 

Mirvetuximab soravatansine is now FDA-approved for the treatment of patients with folate receptor alpha-positive, platinum-resistant ovarian cancer

Treatment with venetoclax appeared to improve responses in patients with relapsed or refractory chronic lymphocytic leukemia, according to findings from a phase 3b study.

The combination of pembrolizumab and olaparib did not appear to improve overall or progression-free survival in patients with nonsquamous non-small cell lung cancer.

APL-1702 is the first nonsurgical treatment for cervical high-grade intraepithelial lesions to show clinical efficacy in a phase 3 trial, making it a potentially groundbreaking option in the field.

The phase 3 CheckMate -9DW study of frontline nivolumab plus ipilimumab in hepatocellular cancer met its primary end point of overall survival vs sorafenib or lenvatinib.

The latest developments across the field of gynecologic oncology were presented at the 2024 Society for Gynecologic Oncology Annual Meeting on Women’s Cancer in San Diego, California, from March 16-18, 2024.

Treatment with nab-Sirolimus demonstrated promising response rates in patients with gynecologic PEComa, according to a subgroup analysis of the phase 2 AMPECT study.

Findings from the phase 3 KEYNOTE-A18 trial showed that pembrolizumab plus chemoradiotherapy improved overall survival in newly diagnosed cervical cancer compared with chemoradiotherapy alone.

The Oncologic Drug Advisory Committee of the FDA found that imetelstat has robust data supporting its use for transfusion-dependent anemia in patients with myelodysplastic syndromes.

The FDA has accepted the new drug application of ensartinib for the treatment of patients with metastatic ALK-positive non-small cell lung cancer.

Introducing a checkpoint inhibitor like nivolumab for patients where chimeric antigen receptor T-cell therapy failed in multiple myeloma is a potential area of interest for researchers.

Pedro Barata, MD, MSc, discussed the importance of the NRG Oncology Semiannual Meeting and the forum it provides for oncologists to collaborate and optimize cancer treatment.

Findings from the phase 3 ECHELON-3 trial demonstrated that brentuximab vedotin plus lenalidomide and rituximab led to improvements in overall survival among patients with diffuse large B-cell lymphoma.

Findings from a post hoc analysis of lurbinectedin for the treatment of small cell lung cancer showed that the agent was more effective and less toxic than topotecan.

Following changes to the manufacturing process, the phase 1 study of NX-2127 in B-cell malignancies has been cleared to continue by the FDA.

Identifying differences in pancreatic cancer subtypes could be at the center of developing targeted treatments in this challenging disease.

Jeremy Ramdial, MD, discussed a phase 1/2 study investigating the GemCloBu conditioning regimen for stem cell transplants in aggressive lymphomas.

Christopher Flowers, MD, MS, discussed the phase 2 ROSEWOOD trial, the study that supported the FDA accelerated approval of zanubrutinib and obinutuzumab for the treatment of relapsed/refractory follicular lymphoma.

In a matched indirect comparison of zanubrutinib vs acalabrutinib, the former showed survival and response improvements in patients with chronic lymphocytic leukemia.

The combination of a novel mTORC1/2 inhibitor with paclitaxel could present a new way of targeting metastatic or persistent endometrial cancer.